Elicio Therapeutics, Inc.

NASDAQ:ELTX

Biotechnology

Healthcare
$2.70 -18.90%

-$0.89 today

Market cap
$51.48M
Beta
1.14
P/E (TTM)
-1.7
EPS (TTM)
-$2.21
52W Low $2.66High $16.00

Volume 0.41M

Average 0.34M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$36.95M

FY 2025 · Annual

Investing Cash Flow

-$16,000.00

FY 2025 · Annual

Financing Cash Flow

$36.70M

FY 2025 · Annual

-13.3% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(26.4M)(28.21M)(35.2M)(51.9M)(39.57M)
Depreciation & Amortization251.45K1.06M1.17M1.18M1.13M
Deferred Income Tax52.96K0000
Stock-Based Compensation617.76K579K1.18M1.45M2.7M
Change in Working Capital872.44K(150K)(57K)3.96M(3.45M)
Accounts Receivables00000
Inventory00000
Accounts Payables30.23K1.13M23K(3.33M)(366K)
Other Working Capital842.21K(1.28M)(80K)7.29M(3.08M)
Other Non-Cash Items667.05K4.54M209K8.24M2.24M
Operating Cash Flow(23.94M)(22.18M)(32.69M)(37.07M)(36.95M)
Capital Expenditures(525.36K)(654K)(66K)(87K)(16K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0034K3K0
Investing Cash Flow(525.36K)(654K)(32K)(84K)(16K)
Debt Repayment14.03M010M19.73M9.87M
Common Stock Issued101.38K82K7M5.64M26.83M
Common Stock Repurchased00(150K)00
Dividends Paid00000
Other Financing Activities314.88K82K21.76M16.96M0
Financing Cash Flow19.39M21.2M38.61M42.32M36.7M
Effect of Forex Changes3K0(68K)22K40K
Net Change in Cash(5.07M)(1.63M)5.89M5.19M(233K)
Free Cash Flow(24.46M)(22.83M)(32.76M)(37.16M)(36.97M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$39.6M
+ D&A$1.1M
+ Stock-Based Comp$2.7M
+ Deferred Tax$0
- Working Capital-$3.4M
+ Other Non-Cash$2.2M
= Operating Cash Flow-$37.0M
- Capex-$16.0K
= Free Cash Flow-$37.0M

Analysis

FY2025 free cash flow is -$37.0M. FCF conversion is 93.4% of net income. Operating cash flow was -$37.0M, with capex of -$16.0K. The largest bridge item is Working Capital at -$3.4M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportAug 13, 2026
8-KCurrent reportAug 13, 2026
4Statement of changes in beneficial ownershipJul 17, 2026
4Statement of changes in beneficial ownershipJul 17, 2026
4Statement of changes in beneficial ownershipJul 17, 2026

Does ELTX generate free cash flow?

Elicio Therapeutics, Inc. (ELTX) generated -$36.97M of free cash flow in fiscal 2025.

How much operating cash flow does ELTX produce?

Operating cash flow was -$36.95M, before capital expenditures of $16,000.00.